Pasithea Therapeutics Corp. – NASDAQ:KTTA

Add to watchlist

$0.7

-2.02

-74.36%

Market closed

Open in 2 days

-51.25%

month

-51.25%

quarter

+565.85%

year

Market Cap	3.32M
Enterprise value	N/A

P/E	-0.72
EV/Sales	-44.46
EV/EBITDA	1.18
Price/Sales	19.53
Price/Book	0.23
PEG ratio	N/A
EPS	-14.3

Revenue	N/A
EBITDA	-16.43M
Income	-16.28M
Revenue Q/Q	N/A
Revenue Y/Y	106.45%

Profit margin	-3536.23%
Oper. margin	-3951.15%
Gross margin	72.51%
EBIT margin	-3951.15%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Pasithea Therapeutics Corp. (NASDAQ:KTTA): Profit margin
Jun 2023	0	-3.76M
Sep 2023	0	-3.61M
Dec 2023	976.30K	-5.04M	-517.07%
Mar 2024	0	-3.86M

Pasithea Therapeutics Corp. (NASDAQ:KTTA): Debt to assets
Jun 2023	38149391	2.55M	6.71%
Sep 2023	30657411	2.28M	7.45%
Dec 2023	26116858	2.71M	10.41%
Mar 2024	22408099	2.52M	11.27%

Pasithea Therapeutics Corp. (NASDAQ:KTTA): Cash Flow
Jun 2023	-3.47M	344.01K	-130.76K
Sep 2023	-2.65M	50.15K	-4.45M
Dec 2023	-3.31M	54.53K	-16.89K
Mar 2024	-4.32M	0	0

Pasithea Therapeutics Corp. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Pasithea Therapeutics Corp.
Employees

Pasithea Therapeutics Corp. (NASDAQ:KTTA): Employee count
Aug 2023	15
Sep 2023	15
Oct 2023	15
Nov 2023	15
Dec 2023	15
Jan 2024	15
Feb 2024	15
Mar 2024	15
Apr 2024	15
May 2024	8
Jun 2024	8
Jul 2024	8

Pasithea Therapeutics Corp.
Hedge Funds Holdings Q1 2023

0.24% -2.13%

of KTTA is owned by hedge funds

6 -5

hedge funds hold KTTA stock

61.60K -569.79K

shares is hold by hedge funds

KTTA hedge funds holdings changes

Pasithea Therapeutics Corp.
Insider Trading

Pasithea Therapeutics Corp. (NASDAQ:KTTA): Insider trades (number of shares)
Period	Buy	Sel
Aug 2022	228245	0
Sep 2022	62356	0
Oct 2022	1000	0
Jun 2023	30000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	2 Jun 2023	STEINMAN LAWRENCE director director	Common Stock	30,000	$0.43	$12,930
Purchase	17 Oct 2022	DELANEY DAVID director director	Common Stock	1,000	$1.11	$1,110
Purchase	28 Sep 2022	CAMAC PARTNERS, LLC director: director:	Common Stock	6,710	$1.16	$7,757
Purchase	1 Sep 2022	CAMAC PARTNERS, LLC director: director:	Common Stock	55,646	$1.13	$62,657
Purchase	29 Aug 2022	CAMAC PARTNERS, LLC director: director:	Common Stock	17,828	$1.15	$20,449
Purchase	19 Aug 2022	LEONITE CAPITAL LLC director: director:	Common Stock	54,644	$1.3	$70,928
Purchase	17 Aug 2022	CAMAC PARTNERS, LLC director: director:	Common Stock	155,773	$1.21	$188,330

KTTA insider trading transactions

Pasithea Therapeutics Corp.
Latest News

Wednesday, 20 November 2024
07:02	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer	globenewswire.com
Thursday, 26 September 2024
18:44	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules	globenewswire.com
08:56	Why Is Pasithea Therapeutics Stock Surging On Thursday?	benzinga.com
07:02	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer	globenewswire.com
Monday, 9 September 2024
08:01	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies	globenewswire.com
Tuesday, 3 September 2024
08:02	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board	globenewswire.com
Wednesday, 28 August 2024
09:11	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Tuesday, 28 May 2024
06:59	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting	globenewswire.com
Monday, 29 April 2024
07:59	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting	globenewswire.com
Wednesday, 24 April 2024
07:59	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers	globenewswire.com
Wednesday, 13 December 2023
09:03	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?	InvestorPlace
Monday, 11 December 2023
11:18	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?	InvestorPlace
Thursday, 7 September 2023
16:14	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire
Wednesday, 29 December 2021
16:16	Hot Penny Stocks For Your January 2022 Watchlist	PennyStocks
Thursday, 23 December 2021
13:58	Top Penny Stocks to Watch During Today's Bull Run	PennyStocks
11:35	KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today	InvestorPlace
Wednesday, 24 November 2021
06:07	Pasithea Therapeutics (KTTA) Stock: Why The Price Jumped Today	Pulse2
Tuesday, 23 November 2021
09:35	Hot Penny Stocks Today: Why Is KTTA Stock Moving?	PennyStocks
08:41	Pasithea Therapeutics (KTTA) Stock: Why The Price Surged Today	Pulse2
Thursday, 14 October 2021
09:13	Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom	Benzinga
Tuesday, 12 October 2021
11:47	Pasithea Therapeutics: Revenues Just Around the Corner	GuruFocus
Monday, 11 October 2021
10:08	Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery	Benzinga
08:34	Pasithea, Evotec Ink Drug Development Pact	Benzinga

Frequently Asked Questions (FAQ)

What's the price of Pasithea Therapeutics Corp. stock today?

One share of Pasithea Therapeutics Corp. stock can currently be purchased for approximately $0.7.
When is Pasithea Therapeutics Corp.'s next earnings date?

Unfortunately, Pasithea Therapeutics Corp.'s (KTTA) next earnings date is currently unknown.
Does Pasithea Therapeutics Corp. pay dividends?

No, Pasithea Therapeutics Corp. does not pay dividends.
How much money does Pasithea Therapeutics Corp. make?

Pasithea Therapeutics Corp. has a market capitalization of 3.32M.
What is Pasithea Therapeutics Corp.'s stock symbol?

Pasithea Therapeutics Corp. is traded on the NASDAQ under the ticker symbol "KTTA".
What is Pasithea Therapeutics Corp.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Pasithea Therapeutics Corp.?

Shares of Pasithea Therapeutics Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Pasithea Therapeutics Corp. have?

As Jul 2024, Pasithea Therapeutics Corp. employs 8 workers, which is 47% less then previous quarter.
When Pasithea Therapeutics Corp. went public?

Pasithea Therapeutics Corp. is publicly traded company for more then 3 years since IPO on 15 Sep 2021.
What is Pasithea Therapeutics Corp.'s official website?

The official website for Pasithea Therapeutics Corp. is pasithea.com.
Where are Pasithea Therapeutics Corp.'s headquarters?

Pasithea Therapeutics Corp. is headquartered at 1111 Lincoln Road, Miami Beach, FL.
How can i contact Pasithea Therapeutics Corp.?

Pasithea Therapeutics Corp.'s mailing address is 1111 Lincoln Road, Miami Beach, FL and company can be reached via phone at +7 025144174.

Pasithea Therapeutics Corp.

pasithea.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

+7 025144174

1111 Lincoln Road
Miami Beach, FL 33139

CIK: 0001841330
ISIN: US70261F2020
CUSIP: 70261F103